Since ETS2 influences tight junction protein expression and intestinal permeability, targeting downstream pathways may help restore barrier integrity and reduce inflammation.[77] Moreover, given the role of ETS2 in fibrosis and colorectal cancer development, anti-fibrotic agents or epigenetic regulators that modify ETS2 expression could be valuable in preventing long-term complications in IBD patients. Here, ETS2 is linked to colorectal cancer.